Download or read book Prescription Drug Labeling and Price Advertising written by United States. Congress. House. Committee on Interstate and Foreign Commerce. Subcommittee on Consumer Protection and Finance and published by . This book was released on 1976 with total page 420 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Prescription Drug Labeling and Price Advertising written by and published by . This book was released on 1977 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Prescription Drug Labeling and Price Advertising written by United States. Congress. House. Committee on Interstate and Foreign Commerce. Subcommittee on Consumer Protection and Finance and published by . This book was released on 1976 with total page 410 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Prescription Drug Labeling and Price Advertising Hearings 94Th Congress 2Nd Session 1976 written by United States. Congress. House. Committee on Interstate and Foreign Commerce and published by . This book was released on 1977 with total page 200 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Prescription drug lebeling and price advertising written by United States. Congress. House. Committee on Interstate and Foreign Commerce. Subcommittee on Consumer Protection and Finance and published by . This book was released on 1976 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Prescription Drug Advertising to Consumers written by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations and published by . This book was released on 1984 with total page 276 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Direct to Consumer Advertising of Prescription Drugs written by and published by . This book was released on 2009 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: So far, Members of the 111th Congress have indicated interest in DTC advertising in the context of drug safety, tax treatment of advertising expenses, risk communication, and general FDA-activity authority and oversight, sometimes in the context of broader discussions of health care costs and reform. [...] The regulations required that companies submit promotional materials to FDA at the same time they make them available to the public.30 The promotion within these materials had to be supported by scientific evidence and be consistent with FDA-approved product labeling.31 The 26 The two agencies acted to avoid overlap based on a 1954 "Working Agreement Between the Federal Trade Commission and the Fo [...] This had to be in the audio portion of the advertisement, and could be in the video portion as well.36 In addition, the advertisement had to describe how the consumer could obtain the full package labeling. [...] FDA requires that any prescription drug advertisement contain "information in brief summary relating to the side effects, contraindications, and effectiveness" of the drug.38 The information on the risks of the product (known as the brief summary) must disclose all the risk-related information in the drug's package labeling. [...] The draft guidance then offered manufacturers three options (other than printing the entire professional labeling) for presenting that information to satisfy the brief summary requirement for DTC print ads.39 The first option would be to reprint the FDA-approved patient labeling in full.40 For the second option, the manufacturer could print a portion of the patient labeling, including the risk inf.
Download or read book The Impact of Direct to consumer Drug Advertising on Seniors Health and Health Care Costs written by United States. Congress. Senate. Special Committee on Aging and published by . This book was released on 2006 with total page 130 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Making Medicines Affordable written by National Academies of Sciences, Engineering, and Medicine and published by National Academies Press. This book was released on 2018-03-01 with total page 235 pages. Available in PDF, EPUB and Kindle. Book excerpt: Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
Download or read book The Economics of Prescription Drug Advertising written by Marta Ewa Wosinska and published by . This book was released on 2002 with total page 250 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Dietary Supplements written by United States. Federal Trade Commission. Bureau of Consumer Protection and published by . This book was released on 1998 with total page 32 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book The Impact of Direct to consumer Advertising on Pharmaceutical Prices and Demand written by Dhaval Dave and published by . This book was released on 2010 with total page 44 pages. Available in PDF, EPUB and Kindle. Book excerpt: Expenditures on prescription drugs are one of the fastest growing components of national health care spending, rising by almost three-fold between 1995 and 2007. Coinciding with this growth in prescription drug expenditures has been a rapid rise in direct-to-consumer advertising (DTCA), made feasible by the Food and Drug Administration's (FDA) clarification and relaxation of the rules governing broadcast advertising in 1997 and 1999. This study investigates the separate effects of broadcast and non-broadcast DTCA on price and demand, utilizing an extended time series of monthly records for all advertised and non-advertised drugs in four major therapeutic classes spanning 1994-2005, a period which enveloped the shifts in FDA guidelines and the large expansions in DTCA. Controlling for promotion aimed at physicians, results from fixed effects models suggest that broadcast DTCA positively impacts own-sales and price, with an estimated elasticity of 0.10 and 0.04 respectively. Relative to broadcast DTCA, non-broadcast DTCA has a smaller impact on sales (elasticity of 0.05) and price (elasticity of 0.02). Simulations suggest that the expansion in broadcast DTCA may be responsible for about 19 percent of the overall growth in prescription drug expenditures over the sample period, with over two-thirds of this impact being driven by an increase in demand as a result of the DTCA expansion and the remainder due to higher prices.
Download or read book The Effect of Direct to Consumer Advertising on Prescription Drug Prices and Sales written by Dhaval Dave and published by . This book was released on 2014 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: The purpose of this study is to estimate the effect of direct-to-consumer advertising (DTCA) of prescription drugs on prescription drug prices and sales. Major increases in broadcast DTCA began in August 1997 when the FDA eliminated the requirement that broadcast advertising present all of the information on the product insert in the advertisement. From 1995 to 2005 DTCA went from $380 million year to $4.24 billion year. Today only the U.S. and New Zealand allow broadcast DTCA. The model shows that a time limited monopoly will initially set prices low and advertising high which will reverse over the patent life. Advertising ends with the expiration of the patent. A pooled data set for all advertised and non-advertised drugs in four major therapeutic classes spanning the period of 1994-2005 was created. Regression models of prescription drug prices and sales on DTCA, detailing, free samples and patent expiration were estimated. Preliminary results suggest that broadcast DTCA has increased prescription drug prices and sales. The expansion in broadcast DTCA may be responsible for about 18 percent of the overall growth in prescription drug expenditures over the sample period. About two-thirds of the growth in expenditures is due to increased sales and about one-third is due to higher prices.
Download or read book Bad Prescription for the First Amendment written by Richard T. Kaplar and published by . This book was released on 1993 with total page 140 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Pain Management and the Opioid Epidemic written by National Academies of Sciences, Engineering, and Medicine and published by National Academies Press. This book was released on 2017-09-28 with total page 483 pages. Available in PDF, EPUB and Kindle. Book excerpt: Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.
Download or read book The Future of Drug Safety written by Institute of Medicine and published by National Academies Press. This book was released on 2007-02-27 with total page 346 pages. Available in PDF, EPUB and Kindle. Book excerpt: In the wake of publicity and congressional attention to drug safety issues, the Food and Drug Administration (FDA) requested the Institute of Medicine assess the drug safety system. The committee reported that a lack of clear regulatory authority, chronic underfunding, organizational problems, and a scarcity of post-approval data about drugs' risks and benefits have hampered the FDA's ability to evaluate and address the safety of prescription drugs after they have reached the market. Noting that resources and therefore efforts to monitor medications' riskâ€"benefit profiles taper off after approval, The Future of Drug Safety offers a broad set of recommendations to ensure that consideration of safety extends from before product approval through the entire time the product is marketed and used.
Download or read book McCarthy on Trademarks and Unfair Competition written by J. Thomas McCarthy and published by Clark Boardman Callaghan. This book was released on 1996 with total page 1186 pages. Available in PDF, EPUB and Kindle. Book excerpt: